Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Brittany Pieniazek knew she had a chance of developing breast cancer. The Dyer resident’s mother and aunt had both been ...
New research suggests that omega-3 and omega-6 fatty acids, found in fish oil, may help prevent various cancers. A study of ...
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...
Diary Based Diet Helps Boost Concentration: Study FindsA recent randomized control crossover study in the Journal of Dairy Science, published by ...
Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...
News Medical on MSN6d
Research in Thailand supports stool DNA as non-invasive alternative for colorectal cancer screeningA recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive ...
Thermo Fisher Scientific has signed an agreement with German molecular genetics company Mainz Biomed, the developer of ...
A new study analysed the efficacy of blood tests versus colonoscopies and stool tests in identifying early-stage CRC. Read ...
Fecal immunochemical tests for post-polypectomy colorectal cancer surveillance may reduce the need for colonoscopy and improve screening adherence. Stool-based post-polypectomy surveillance strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback